Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

Meda Aktiebolag Successfully Amends MTN Terms and Conditions and Exercises Call Option

SOLNA, Sweden, Dec. 6, 2017 /PRNewswire/ --

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect

Today, Meda Aktiebolag (the "Company") held two noteholders' meetings pursuant to the summons sent on 7 November 2017 to the noteholders of the:

(i) SE0005132180 ? STIBOR 3M +2.85% 2013/2018 notes (the "2018 Notes"); and

(ii) SE0005991635 ? STIBOR 3M +1.65% 2014/2019 notes (the "2019 Notes" and together, with the 2018 Notes, the "Notes"),

issued under the SEK 7,000,000,000 medium term notes programme of the Company originally established on 25 May 2012 (as updated on 31 July 2012, 12 May 2014 and 16 July 2015), for the purposes of approving an amendment to the terms and conditions of the Notes to insert an early redemption call option (the "Call Option").

A sufficient number of noteholders were present in order for each noteholders' meeting to be quorate and a requisite majority of the voting noteholders at each noteholders meeting voted in favour of approving the proposed amendment to the terms and conditions.

As at the date hereof, the terms and conditions of the Notes have been effectively amended and the Company has given notice to the noteholders of each series of Notes that it will exercise the Call Option in accordance with the amended terms and conditions.

For further information regarding the amended terms and conditions and the Call Option, please refer to Skandinaviska Enskilda Banken AB (publ) acting as Tabulation and Paying Agent.

The Tabulation and Paying Agent:


Skandinaviska Enskilda Banken AB (publ)
Stjärntorget 4
SE-106 40 Stockholm
Tel: +46 (0)8 763 80 96
Email: sebtenderagent@seb.se
Attention: SEB Tender Agent


The Board of directors
Meda Aktiebolag

For further inquiries, please contact:

Melissa Trombetta,
Head of Global Investor Relations
Mylan NV.
Tel: +1(917)262-2958

This is information that Meda Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:45 noon CET on 6 December 2017.

Meda Aktiebolag is a leading international specialty pharma company. Meda's products are sold in more than 120 countries worldwide and the company is represented by its own organizations in close to 60 countries. Find out more, visit www.meda.se.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:


Press release (PDF)



These press releases may also interest you

24 mai 2018
Eisai Inc. and Merck , known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental New Drug Application (sNDA) for lenvatinib for the potential...

24 mai 2018
The International Center for Journalists will honor Arthur Sulzberger Jr., chairman of The New York Times Company, along with CNN correspondent Nima Elbagir and digital trailblazers from the Philippines and Venezuela at its Awards Dinner on Nov. 8....

24 mai 2018
Nearly a million people visit the emergency room every year for bee and wasp stings. In many cases, patients and parents can treat the symptoms of less severe reactions to a sting from home, while a small percentage suffering a more dangerous...

24 mai 2018
PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, and medical device sectors, today announced the winners of its 4th Annual ELITE Awards. The ELITE (Exceptional ? Leaders ? Innovators ? Transformers...

22 mai 2018
The following is a statement from John Auerbach, President and CEO, of Trust for America's Health (TFAH) on the introduction of the Senate HELP Committee's Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act:...

22 mai 2018
NanoViricides, Inc. (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its third quarter of financial year 2018 in a...

News published on 6 december 2017 at 07:16 and distributed by: